Related Experiment Video

Updated: Aug 20, 2026

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome
06:04

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome

Published on: September 27, 2024

[Thrombocytic hemostasis in hypertensive patients with metabolic syndrome and its correction with lovastatin]

I N Medvedev, N I Gromnatskiĭ, I V Volobuev

    Klinicheskaia Meditsina
    |December 9, 2004
    PubMed

    Insights

    Lovastatin effectively treats dyslipidemia and reduces platelet activity in patients with arterial hypertension and metabolic syndrome. Long-term use with diet and exercise is recommended for sustained benefits like weight loss and improved insulin resistance.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Pharmacology

    Background:

    • Arterial hypertension (AH) and metabolic syndrome (MS) often coexist, leading to complex health issues.
    • Dyslipidemia and impaired intravascular platelet activity (IPA) are common complications in patients with AH + MS.
    • Understanding the impact of pharmacological interventions on these comorbidities is crucial for effective patient management.

    Purpose of the Study:

    • To evaluate the efficacy of lovastatin in correcting dyslipidemia and IPA in patients with concurrent AH and MS.
    • To assess the effects of lovastatin on anthropometric parameters, lipid profiles, and oxidative stress markers.
    • To investigate the impact of lovastatin on intrathrombocytic mechanisms and platelet function.

    Main Methods:

    • A one-month study involving 18 patients with AH + MS treated with lovastatin.
    • Assessment of anthropometric data, blood lipid spectrum, plasma, and lipid peroxidation.
    • Evaluation of antioxidative status, platelet function, and intravascular platelet activity (IPA).

    Main Results:

    • Lovastatin successfully corrected dyslipoproteinemia and the peroxidation syndrome in patients with AH + MS.
    • The drug optimized intrathrombocytic regulatory mechanisms and inhibited in vivo increased platelet activity.
    • These beneficial effects on platelet activity may be sustained with continued lovastatin use.

    Conclusions:

    • Lovastatin demonstrates significant efficacy in managing dyslipidemia and hyperactive platelets in patients with arterial hypertension and metabolic syndrome.
    • Sustained improvement in body weight and insulin resistance necessitates long-term lovastatin therapy combined with lifestyle modifications.
    • Lovastatin offers a therapeutic option for addressing multiple interrelated health issues in this patient population.

    Related Concept Videos

    Hypertension II: Pathophysiology01:29

    Hypertension II: Pathophysiology

    Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
    Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

    Hypertension IV: Drug Therapy and Lifestyle Modifications

    Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

    Hypertension III: Clinical Manifestations and Diagnostic Studies

    Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Hypertension and Regulation of Blood Pressure01:18

    Hypertension and Regulation of Blood Pressure

    Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...